atranorin has been researched along with Breast Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Harikrishnan, A; Lakshmi, B; Nandi, S; Oshin, K; Prashantha, CN; Shah, T; Shanmugavalli, R; Theres, S; Togam, R; Veena, V | 1 |
| Bačkor, M; Hrčková, G; Koptašíková, L; Solár, P; Solárová, Z; Velebný, S | 1 |
2 other study(ies) available for atranorin and Breast Neoplasms
| Article | Year |
|---|---|
Atranorin, an antimicrobial metabolite from lichen
Topics: Anti-Infective Agents; Apoptosis; Ascomycota; Breast Neoplasms; Cell Line, Tumor; Female; Humans; Hydroxybenzoates; Lichens; Molecular Docking Simulation; Proto-Oncogene Proteins c-akt; Proto-Oncogene Proteins c-bcl-2 | 2021 |
Murine breast carcinoma 4T1 cells are more sensitive to atranorin than normal epithelial NMuMG cells in vitro: Anticancer and hepatoprotective effects of atranorin in vivo.
Topics: Animals; Antineoplastic Agents; Breast; Breast Neoplasms; Caspase 3; Cell Cycle; Cell Line; Cell Line, Tumor; Female; Hydroxybenzoates; Liver; Mammary Neoplasms, Experimental; Mice; Mice, Inbred BALB C; Oxidative Stress | 2016 |